Evidence map›Paper›PMID 31358584›Full record

ArticleAntimicrobial agents and chemotherapy2019

Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase.

Clyde A Smith, Nichole K Stewart, Marta Toth, Sergei B Vakulenko

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Clyde A SmithStanford Synchrotron Radiation Lightsource, Stanford University, Menlo Park, California, USA csmith@slac.stanford.edu svakulen@nd.edu.
Nichole K StewartDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
Marta TothDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
Sergei B VakulenkoDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA csmith@slac.stanford.edu svakulen@nd.edu.
University of Notre Dame · USStanford University · US

Funding

ZWITTERION SURFACTANT DDMAB FOR IMPROV STABIL OF PROTEINP41RR001209 · NCRR · STANFORD UNIVERSITY · PI SCOTT, EMILY E · 1985 to 2011
$38.9M
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Resistance to Carbapenem Antibiotics in Acinetobacter baumanniiR01AI114668 · NIAID · UNIVERSITY OF NOTRE DAME · PI BUYNAK, JOHN D, VAKULENKO, SERGEI · 2015 to 2020
$3.1M
Antibiotics Designed to Counter Resistant 21st Century PathogensR15AI142699 · NIAID · SOUTHERN METHODIST UNIVERSITY · PI BUYNAK, JOHN D · 2019 to 2019
$437k
NCRR NIH HHS P41 RR001209NIAID NIH HHS R01 AI114668NIAID NIH HHS R15 AI142699NIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

Carbapenem-hydrolyzing class D carbapenemases (CHDLs) are enzymes that produce resistance to the last-resort carbapenem antibiotics, severely compromising the available therapeutic options for the treatment of life-threatening infections. A broad variety of CHDLs, including OXA-23, OXA-24/40, and OXA-58, circulate in

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsCatalytic DomainDoripenemHydrophobic and Hydrophilic InteractionsImipenemMeropenemMicrobial Sensitivity TestsProtein Structure, SecondaryAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsDoripenemImipenemMeropenemantibiotic resistancedrug resistance mechanisms

Identifiers

PMID31358584
PMCPMC6761500
OpenAlexW2965798939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.